Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
← catalyst calendarSponsored by Faes Farma, S.A. (industry) · FAE.MC — their whole pipeline →.
Phase
Phase 3
Status
Unknown status
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
376estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Mar 2024 | estimated | When the study began enrolling |
| Primary completion | Aug 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-12-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colitis, Ulcerative
Intervention
- Drug: Mesalazine
Primary outcome
what the primary-completion date above is the date OFTo assess the percentage of patients with clinical remission [Mayo Modified Score (MMS) ≤ 2] and Endoscopic remission [Mayo Endoscopic Score (MES) ≤ 1] after 8 weeks of treatment.
measured 8 weeks
Permalink · FAE.MC's whole pipeline · Catalyst calendar · Every registered study · What changed